<DOC>
	<DOCNO>NCT00004938</DOCNO>
	<brief_summary>OBJECTIVE : I . Evaluate efficacy fluconazole patient lymphocutaneous visceral sporotrichosis .</brief_summary>
	<brief_title>Phase II Study Fluconazole Lymphocutaneous Visceral Sporotrichosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat daily oral fluconazole 24 month . Follow-up continue least 1 year .</detailed_description>
	<mesh_term>Sporotrichosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Presumptive evidence sporotrichosis Cultureproven sporotrichosis determine study Relapsing disease follow antifungal therapy eligible culture positive Sporothrix schenckii prior entry No lifethreatening disease No central nervous system sporotrichosis Prior/Concurrent Therapy No concurrent drug know react fluconazole No 3 day systemic antifungal current sporotrichosis episode Patient Characteristics Hepatic : Liver function test great 5 time normal Other : No HIV infection No pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>fungal infection</keyword>
	<keyword>rare disease</keyword>
	<keyword>sporotrichosis</keyword>
</DOC>